Skip to content Skip to footer
Subscribe Now
NEWS

Boulevard Bio Inks ~$1.62B Licensing Deal with METiS TechBio for MTS-128

Shots: METiS TechBio has granted Boulevard worldwide development, manufacturing, and commercialization rights to MTS-128, a trispecific T-cell engager (TCE) program As per the deal, METiS TechBio will receive a $20M upfront payment & ~$1.6B in development, regulatory, & commercial milestone payments, in addition to tiered royalties on product sales MTS-128 is a trispecific T-cell engager…
June 30, 2026

Read more

NEWS

LENZ Therapeutics Partners with Arrotex Pharmaceuticals to Commercialize Vizz in Australia and New Zealand

Shots: LENZ has entered into an exclusive license & commercialization agreement with Arrotex to register & commercialize Vizz (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in Australia & New Zealand As per the deal, Arrotex will obtain exclusive commercialization rights for Vizz for the treatment of presbyopia in Australia & New Zealand. In return,…
June 26, 2026

Read more

NEWS

Abbisko Therapeutics Inks ~$1.9B Multi-Target R&D Deal with Eli Lilly

Shots: Abbisko Therapeutics has entered into a strategic research collaboration & license agreement with Eli Lilly to discover & develop novel therapeutics across multiple targets Abbisko will leverage its early-stage drug discovery platform, R&D ecosystem, & development expertise to conduct discovery & early-stage development of novel therapeutics against disease targets selected by Lilly As per…
June 24, 2026

Read more

NEWS

Nuvectis Expands Pipeline with ~ $1.46B Ex-China Licensing Deal for Two Late-Stage Assets from Haisco

Shots: Nuvectis has licensed exclusive ex-China rights to NXP100 (HSK39297; QD, PO), a Complement Factor B inhibitor, & NXP200 (HSK42360), a brain-penetrant paradox-breaker BRAF inhibitor from Haisco, transforming the company into a late-stage development player  As per the deal, Haisco will receive ~$40M in upfront & near-term payments, plus up to $1.421B in development,…
June 23, 2026

Read more

NEWS

Dimerix Inks a ~$340M Deal with Everest Medicine to Commercialize DMX-200 in Greater China, South Korea, and Southeast Asia

Shots: Dimerix has granted Everest exclusive rights to commercialize DMX-200 for all indications incl. FSGS, in Greater China, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam & Philippines; Dimerix will retain rights outside the licensed regions Dimerix will continue funding & conducting the P-III (ACTION3) study, while Everest will manage regulatory filings, maintenance of the regulatory…
June 16, 2026

Read more

NEWS

CytomX and Regeneron Expand Tumor-Activated Bispecific Cancer Therapy Collaboration in Potential ~$4B Deal

Shots: CytomX has expanded its collaboration & licensing agreement with Regeneron to develop conditionally-activated bispecific cancer therapies using CytomX’s Probody platform & Regeneron’s Veloci-B BsAb development platform As per the expanded deal, the companies will continue joint discovery efforts to identify & validate conditionally active BsAbs, with Regeneron assuming responsibility for all preclinical & clinical development, commercialization,…
June 4, 2026

Read more

NEWS

Everest Medicine Licenses Civorebrutinib to Travere Therapeutics in a ~$1.14B Deal

Shots: Travere has entered into an exclusive licensing & collaboration agreement with Everest Medicines for the development & commercialization of civorebrutinib (EVER001) worldwide (excl. China & certain countries in East & Southeast Asia) As per the deal, Everest will receive $112.5M upfront & ~$1.03B in cash payments tied to development, regulatory & commercial milestones across…
June 2, 2026

Read more

NEWS

Haisco Enters ~$3.05B License and Research Collaboration with Lilly to Develop Novel Medicines Across Multiple Therapeutic Areas

Shots: Haisco Pharmaceutical has entered into a licensing & research collaboration with Eli Lilly to develop novel medicines across multiple therapeutic areas As per the deal, Haisco will be responsible for the discovery & identification of ~5 target programs, while Lilly will lead IND-enabling studies, clinical development, & commercialization Lilly will gain exclusive global rights…
June 1, 2026

Read more

Load more